Emmaus Life Sciences, Inc. · OTC:EMMA
Emmaus Life Sciences — MYnd Analytics — Investor Presentation (January 2018)
25 slides from Emmaus Life Sciences's investor presentation, Jan 5, 2018
Slide 1: Greater Access to More Effective Treatments Reduces Total Cost of Care
GREATER ACCESS TO MORE EFFECTIVE TREATMENTS REDUCES TOTAL COST OF CARE January 2018 Investor Presentation NASDAQ: MYND
Slide 2: Disclaimer
Investor Presentation DISCLAIMER This presentation contains “forward - looking statements” pursuant to the safe - harbor provisions of the Private Securities Litigation Reform Act of 1995 that include information relating to future events, future financial performance, strategies, expectations, comp
Slide 3: MYnd Analytics: Telemedicine and Data Analytics
Investor Presentation 3 MYND ANALYTICS (NASDAQ:MYND) Telemedicine Data Analytics/ Machine Learning Unique first mover in treating mental health conditions through the combination of telemedicine and data analytics/ artificial (augmented) intelligence to improve health care delivery and reduce costs.
Slide 4: Investment Highlights
Investor Presentation 4 INVESTMENT HIGHLIGHTS x Initial focus is the $147 billion underserved mental health market 1 o Highest worldwide disease burden and single largest reason for work disability o Over $6k additional yearly health care costs for individuals not adequately treated for co - morbid
Slide 5: Mental Health - Incidence & Cost
Investor Presentation 5 MENTAL HEALTH - INCIDENCE & COST • Globally, an estimated 3 0 0 million people suffer from depression and 60 million have Bipolar affective disorder . (1) • Anxiety disorders are the most common mental illness in the U.S. affecting 40 million adults. (2) • It is estimated tha
Slide 6: Economic Impact
Investor Presentation Source: Melek S., Norris D., Paulus J.: Economic Impact of Integrated Medical - Behavioral Healthcare: Implications for Psychiatry. Prepared for APA; 2014, pp.1 - 39. 6 ECONOMIC IMPACT (IN 2012) Population % with Behavioral Health (BH) Diagnosis Per - member per - month (PMPM)
Slide 7: Trial and Error Pharmacotherapy
Investor Presentation 7 Thomas R. Insel, MD 2009 - 2010 “ Current medications are not sufficient for most patients... We still do not know who will respond to a specific treatment. Even for the fraction of patients who ultimately respond, clinicians often must resort to trial and error before findin
Slide 8: Problem and Solution: Service Lines
Investor Presentation Problem Looming crisis in access to care: • Psychiatrist shortage • Waiting lists are high • 70% of mental health is treated by PCPs • Low attendance and adherence to treatment (avg = 2 visits) Clinicians often rely on trial and error prescribing for depression, anxiety, PTSD a
Slide 9: Telepsychiatry
Investor Presentation 9 TELEPSYCHIATRY • Telepsychiatry involves the use of video conferencing and telecommunication equipment to conduct real time mental health consultation between a clinician and patient • Ideal for individuals living in underserved areas or those with limited access to services,
Slide 10: Arcadian
Investor Presentation 10 ARCADIAN • Arcadian specializes in the delivery of mental health services through a network of social workers, therapists and psychiatrists throughout the United States • Offers a suite of services including telepsychiatry, teletherapy, digital patient screening, curbside co
Slide 11: Healthcare AI Market
Investor Presentation HEALTHCARE AI MARKET • According to Accenture, when combined, key clinical health artificial intelligence (AI) applications can potentially create $150 billion in annual savings for the United States healthcare economy by 2026 1 • In just the next five years, the health AI mark
Slide 12: How It Works
Investor Presentation 12 HOW IT WORKS • An electroencephalogram (EEG) is a completely painless, non - invasive test that records your brain’s electrical activity and provides a basis for comparison against others within the Psychiatric Electroencephalography Evaluation Registry (“PEER”) database • M
Slide 13: Interim Findings from the 4th Clinical Trial - Walter Reed PEER Trial
Investor Presentation 5 2 Peer Followed Standard of Care 144% 75% 75% 139% Depression SuicidalityGlobal Improvement PTS P e r c e n t 13 INTERIM FINDINGS FROM THE 4 TH CLINICAL TRIAL – WALTER REED PEER TRIAL Patients whose physicians followed PEER had more statistically significant improvement than
Slide 14: Independent Validation
Investor Presentation 14 INDEPENDENT VALIDATION From a rapidly growing research base, 100 peer - reviewed studies* of Quantitative EEG (QEEG) neurometrics (n = 6,025) have demonstrated the utility of these markers, including: • 12 randomized controlled trials of QEEG neurometrics for predicting medi
Slide 15: What Doctors Say
Investor Presentation 15 WHAT DOCTORS SAY “Why are we treating an organ, the brain, without measuring the effect of our treatment on the organ? There are over 100 medications available for the treatment of behavioral disorders. The core problem is not that we need three more, the problem is that we
Slide 16: Target Business Model: Payors
Investor Presentation 16 TARGET BUSINESS MODEL: PAYORS VA/Military Where suicide rates are high and need for innovative and effective mental health care is high Managed Care Payers and health systems seeking to improve clinical outcomes and lower health care costs Case study : Horizon Healthcare Ser
Slide 17: Target Business Model: Provider Direct
Investor Presentation 17 TARGET BUSINESS MODEL Provider Direct Multi - practitioner provider groups seeking to provide value - based care and cutting edge objective measurement tools that are reimbursed Multi - Practice Groups Over 15% of patients have mental health concerns but expertise not presen
Slide 18: Experienced Leadership
Investor Presentation EXPERIENCED LEADERSHIP Board of Directors George C. Carpenter, IV – President & CEO • Over 25 years of experience in healthcare technology and business development • MBA in Finance from the University of Chicago, BA from Dartmouth College Brian MacDonald – Chief Technology Offi
Slide 19: Milestones: Month Goals
Investor Presentation 19 MILESTONES: 12 MONTH GOALS 1 Establish 2 nd paid pilot program(s) with managed care companies and health systems seeking to improve clinical outcomes and lower health care costs 2 Publish pharmacoeconomic benefits when providers use the PEER report on - line tool 3 Penetrate
Slide 20: Capitalization & Balance Sheet
Investor Presentation 20 CAPITALIZATION & BALANCE SHEET Common Stock Issued and Outstanding* 4,360,561 Total Shares of Common Stock Underlying Issued Options* 624,083 Total Shares of Common Stock Underlying Issued Warrants* 4,567,672 Fully Diluted* 9,552,316 Cash (9/30/2017) $ 5,449,000 Long - Term
Slide 21: Summary
Investor Presentation 21 SUMMARY With telemedicine, we can deliver mental health services where and when the patient needs them including the privacy of one’s own home. With artificial intelligence, machine learning and data analytics, we can analyze massive quantities of data to recognize patterns,
Slide 22: Contact
Investor Presentation 22 CONTACT Robin L. Smith, MD, MBA, Chairman of the Board tel : 917 - 691 - 7409 email: robin@robinlsmith.com George C. Carpenter IV, President and Chief Executive Officer tel: 949 - 697 - 2161 email: gcarpenter@myndanalytics.com Don D’Ambrosio, Chief Financial Officer tel : em
Slide 23: Digital Health Care: Investments
Investor Presentation DIGITAL HEALTH CARE: INVESTMENTS MYND is in one of the hottest areas of AI/digital health care 23 1/16 - 8/16
Slide 24: Digital Health Care: 2016 Largest Acquisitions
Investor Presentation Source: RockHealth, 2016 https:// rockhealth.com /reports/digital - health - exits - 2016 - ytd - 112 - digital - health - acquisitions - and - two - ipos/. DIGITAL HEALTH CARE In 2016 the 10 largest acquisitions brought in over $11B for shareholders 24 Target Acquired By Acqui
Slide 25: Mental Health - Today
Investor Presentation 25 MENTAL HEALTH - TODAY Problem : • There is a shortage of psychiatrists so most treatment for non - psychotic mental health disorders is delivered by non - psychiatrists. 2 • Clinicians often rely on trial and error prescribing for depression, anxiety, PTSD and other mental h
MYnd Analytics — Investor Presentation (January 2018) on 6ix